Polycationic phosphorous dendrimer potentiates multiple antibiotics against drug-resistant mycobacterial pathogens
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Mycobacterium tuberculosis (Mtb), causative agent of tuberculosis (TB) and non-tubercular mycobacterial (NTM) pathogens such as Mycobacterium abscessus are one of the most critical concerns worldwide due to increased drug-resistance resulting in increased morbidity and mortality. Therefore, focusing on developing novel therapeutics to minimize the treatment period and reducing the burden of drug-resistant Mtb and NTM infections are an urgent and pressing need. In our previous study, we identified anti-mycobacterial activity of orally bioavailable, non-cytotoxic, polycationic phosphorus dendrimer 2G0 against Mtb. In this study, we report ability of 2G0 to potentiate activity of multiple classes of antibiotics against drug-resistant mycobacterial strains. The observed synergy was confirmed using time-kill kinetics and revealed significantly potent activity of the combinations as compared to individual drugs alone. More importantly, no re-growth was observed in any tested combination. The identified combinations were further confirmed in intra-cellular killing assay as well as murine model of NTM infection, where 2G0 potentiated the activity of all tested antibiotics significantly better than individual drugs. Taken together, this nanoparticle with intrinsic antimycobacterial properties has the potential to represents an alternate drug candidate and/or a novel delivery agent for antibiotics of choice for enhancing the treatment of drug-resistant mycobacterial pathogens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:173 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 173(2024) vom: 27. März, Seite 116289 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Imran, Mohmmad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AMR |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2024.116289 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369423976 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369423976 | ||
| 003 | DE-627 | ||
| 005 | 20240328000048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2024.116289 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM369423976 | ||
| 035 | |a (NLM)38452653 | ||
| 035 | |a (PII)S0753-3322(24)00170-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Imran, Mohmmad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polycationic phosphorous dendrimer potentiates multiple antibiotics against drug-resistant mycobacterial pathogens |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Mycobacterium tuberculosis (Mtb), causative agent of tuberculosis (TB) and non-tubercular mycobacterial (NTM) pathogens such as Mycobacterium abscessus are one of the most critical concerns worldwide due to increased drug-resistance resulting in increased morbidity and mortality. Therefore, focusing on developing novel therapeutics to minimize the treatment period and reducing the burden of drug-resistant Mtb and NTM infections are an urgent and pressing need. In our previous study, we identified anti-mycobacterial activity of orally bioavailable, non-cytotoxic, polycationic phosphorus dendrimer 2G0 against Mtb. In this study, we report ability of 2G0 to potentiate activity of multiple classes of antibiotics against drug-resistant mycobacterial strains. The observed synergy was confirmed using time-kill kinetics and revealed significantly potent activity of the combinations as compared to individual drugs alone. More importantly, no re-growth was observed in any tested combination. The identified combinations were further confirmed in intra-cellular killing assay as well as murine model of NTM infection, where 2G0 potentiated the activity of all tested antibiotics significantly better than individual drugs. Taken together, this nanoparticle with intrinsic antimycobacterial properties has the potential to represents an alternate drug candidate and/or a novel delivery agent for antibiotics of choice for enhancing the treatment of drug-resistant mycobacterial pathogens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AMR | |
| 650 | 4 | |a Non-tuberculous mycobacteria | |
| 650 | 4 | |a Polycationic-phosphorous dendrimers | |
| 650 | 4 | |a Synergy | |
| 650 | 4 | |a in vivo activity | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Dendrimers |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Singh, Shriya |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Mohammad Naiyaz |e verfasserin |4 aut | |
| 700 | 1 | |a Malik, Pradip |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Atri |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Karan Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Umesh D |e verfasserin |4 aut | |
| 700 | 1 | |a Mugale, Madhav N |e verfasserin |4 aut | |
| 700 | 1 | |a Mitra, Kalyan |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Kishore K |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, Sidharth |e verfasserin |4 aut | |
| 700 | 1 | |a Mignani, Serge |e verfasserin |4 aut | |
| 700 | 1 | |a Apartsin, Evgeny |e verfasserin |4 aut | |
| 700 | 1 | |a Majoral, Jean-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Dasgupta, Arunava |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 173(2024) vom: 27. März, Seite 116289 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:173 |g year:2024 |g day:27 |g month:03 |g pages:116289 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116289 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 173 |j 2024 |b 27 |c 03 |h 116289 | ||